4.7 Article

The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 911, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2021.174560

Keywords

Respiratory diseases; Phytocannabinoids; Synthetic cannabinoids; Endocannabinoids; Inhibitors of endocannabinoid degradation; Cannabinoids receptors

Funding

  1. Medical University of Biaystok (Poland) [SUB/2/DN/21/003/2213]

Ask authors/readers for more resources

Cannabinoids are being considered as potential compounds for the treatment of respiratory diseases due to their beneficial properties such as anti-inflammatory, antioxidant, anti-cancer, and anti-fibrotic effects exerted through CB1 and CB2 receptors. Research has shown positive effects of cannabinoids in the respiratory system, but few studies have explored the negative impacts of these compounds.
The global incidence of respiratory diseases and complications is increasing. Therefore, new methods of treatment, as well as prevention, need to be investigated. A group of compounds that should be considered for use in respiratory diseases is cannabinoids. There are three groups of cannabinoids - plant-derived phytocannabinoids, synthetic cannabinoids, and endogenous endocannabinoids including the enzymes responsible for their synthesis and degradation. All cannabinoids exert their biological effects through either type 1 cannabinoid receptors (CB1) and/or type 2 cannabinoid receptors (CB2). In numerous studies (in vitro and in vivo), cannabinoids and inhibitors of endocannabinoid degradation have shown beneficial anti-inflammatory, antioxidant, anti-cancer, and anti-fibrotic properties. Although in the respiratory system, most of the studies have focused on the positive properties of cannabinoids and inhibitors of endocannabinoid degradation. There are few research reports discussing the negative impact of these compounds. This review summarizes the properties and mechanisms of action of cannabinoids and inhibitors of endocannabinoid degradation in various models of respiratory diseases. A short description of the effects selected cannabinoids have on the human respiratory system and their possible use in the fight against COVID-19 is also presented. Additionally, a brief summary is provided of cannabinoid receptors properties and their expression in the respiratory system and cells of the immune system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available